cilia and flagella associated protein 52Genealiases: HTX10 · WDR16 · WDRPUH
Q-omics provides the consensus-scored CFAP52 profile across patient tissues and cancer cell-line models. CFAP52 expression is associated with patient survival in 24 of 34 cancer types, with the highest sampling consensus in BLCA. Among the 18 cancer types available for tumor–normal comparison, CFAP52 is differentially expressed in 13, with the highest sampling consensus in KICH. Additionally, CFAP52 RNA expression shows 17,037 significant gene co-expression associations, with the highest sampling consensus in KIRP. Together, these results highlight BLCA, KICH, and KIRP as cancer lineages where CFAP52 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for CFAP52 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes CFAP52 survival associations across molecular data types. CFAP52 RNA expression shows survival associations in the most cancer types (24), followed by mutation status (9) and mass-spec protein abundance (2). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible CFAP52 RNA expression–survival associations across cancer types. High CFAP52 expression shows unfavorable associations in BLCA and ESCA, but favorable associations in KIRP, MESO, BRCA and PCPG. The BLCA Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p = .011). Together, the overview and detailed table identify BLCA as the clearest survival context for CFAP52 RNA expression.
This table summarizes CFAP52 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 13, while mass-spec protein shows differences in 2. The strongest signals are observed in KICH for RNA and LUAD for protein.
This table ranks reproducible tumor–normal expression differences for CFAP52. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. CFAP52 shows lower tumor expression in KICH, LUAD, LUSC and THCA and higher tumor expression in BLCA and KIRP. The KICH box plot shows higher CFAP52 RNA expression in normal versus tumor tissue (log2 FC = −0.513, t-test p < 0.001).
This table shows molecular features associated with CFAP52 in patient tissues and cancer cell lines. In patient samples, CFAP52 shows the broadest associations at the RNA and protein expression levels, with KIRP recurring as the lineage with the largest associated feature set. In cancer cell lines, CFAP52 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BREAST, while CRISPR and shRNA rows add functional-dependency signals in CNS and UPPER_AERODIGESTIVE_TRACT.
